Sunshine Biopharma Inc. (SBFMW) company profile
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
About Sunshine Biopharma
Pharmaceutical Preparations, SIC 2834
Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of medicines across therapeutic areas such as oncology and antivirals. Through its subsidiary Nora Pharma, the company offers generic prescription medications addressing cardiovascular health, central nervous system disorders, oncology, diabetes, and other conditions. It also operates a subsidiary named Sunshine Biopharma Canada, which develops and sells over-the-counter dietary supplements. In addition, Sunshine Biopharma conducts proprietary research programs focused on an mRNA-based therapy for liver cancer and a protease inhibitor targeting SARS Coronaviruses. Its customers include pharmacies and consumers.
The company's commercial generic drugs are marketed in Canada, primarily in Quebec, with smaller presences in Ontario, Alberta, and British Columbia. It distributes 71 generic prescription drugs and holds 22 additional candidates in development. Over-the-counter supplements are sold exclusively through the Canadian Amazon marketplace. The company maintains its principal executive offices in Fort Lauderdale, Florida.
Summary of the business section of Sunshine Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sunshine Biopharma Inc.
- Headquarters
- Fort Lauderdale, FL
- Address
- 333 Las Olas Way, Cu4 Suite 433 33301
- Phone
- (954) 330-0684
- Website
- sunshinebiopharma.com
- Employees
- 50, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Colorado
- Fiscal year ends
- December 31
- Auditor
- Bush & Associates CPA LLC, Henderson, Nevada
Stock & identifiers
- Ticker
- SBFMW
- Other tickers
- SBFM
- Exchange
- Nasdaq
- IPO date
- Feb 15, 2022
- Shares outstanding
- 4M, Aug 13, 2026
- Public float
- $7.06M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jun 1, 2026; 1-for-20 reverse, Aug 8, 2024; 1-for-100 reverse, Apr 17, 2024; 1-for-200 reverse, Mar 21, 2022; 1-for-20 reverse, May 1, 2020; 1-for-20 reverse, Apr 12, 2019
- SEC CIK
- 1402328
- CUSIP
- 867781502
- ISIN
- US8677815024
- FIGI
- BBG015CDY4D5
- LEI
- 5299005Y64EHRQDQ2Q25
- EIN
- 20-5566275
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michel Roy | Chief Commercial Officer | 1 |
| David Natan | Director | 68,300 |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Total | vs. prior year |
|---|---|---|---|---|
| Dr. Steve N. Slilaty Chief Executive Officer and Director | $411.59K | $800.00K | $1.21M | +116% |
| Camille Sebaaly Chief Financial Officer | $302.03K | $50.00K | $352.03K | -49% |
| Dr. Abderrazzak Merzouki Chief Operating Officer and Director | $241.63K | $45.00K | $286.63K | +10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of the date of this report, we have a total of 50 employees, all of whom are full-time.”
Corporate history
Events identified from SEC filings